|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for FABP3 |
 Gene summary |
| Basic gene Info. | Gene symbol | FABP3 |
| Gene name | fatty acid binding protein 3, muscle and heart | |
| Synonyms | FABP11|H-FABP|M-FABP|MDGI|O-FABP | |
| Cytomap | UCSC genome browser: 1p33-p32 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004102.3, | |
| Description | Fatty acid-binding protein 3, musclefatty acid binding protein 11fatty acid-binding protein, heartheart-type fatty acid-binding proteinmammary-derived growth inhibitormuscle fatty acid-binding protein | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 134651 | |
| HGNC : HGNC | ||
| HPRD : 00613 | ||
| Protein | UniProt: P05413 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_FABP3 | |
| BioGPS: 2170 | ||
| Pathway | NCI Pathway Interaction Database: FABP3 | |
| KEGG: FABP3 | ||
| REACTOME: FABP3 | ||
| Pathway Commons: FABP3 | ||
| Context | iHOP: FABP3 | |
| ligand binding site mutation search in PubMed: FABP3 | ||
| UCL Cancer Institute: FABP3 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for FABP3 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L116 | L114F | HNSC | 1 | F17 | D18V | OV | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for FABP3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F17 | D18V | -0.76292933 | L116 | L114F | -0.41230149 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for FABP3 from PDB |
| Top |
| Differential gene expression and gene-gene network for FABP3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for FABP3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0026848 | Muscular Diseases | 1 | Biomarker |
| umls:C0027540 | Necrosis | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for FABP3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of FABP3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | STE | STEARIC ACID | 3wxq | A | L116 |
| Top |
| Conservation information for LBS of FABP3 |
| Multiple alignments for P05413 in multiple species |
| LBS | AA sequence | # species | Species | A34 | ATRQVASMTKP | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A34 | ATRQVGNMTKP | 1 | Bos taurus | A76 | FDETTADDRKV | 2 | Homo sapiens, Bos taurus | A76 | FDEVTADDRKV | 2 | Mus musculus, Rattus norvegicus | D77 | DETTADDRKVK | 2 | Homo sapiens, Bos taurus | D77 | DEVTADDRKVK | 2 | Mus musculus, Rattus norvegicus | D78 | ETTADDRKVKS | 2 | Homo sapiens, Bos taurus | D78 | EVTADDRKVKS | 2 | Mus musculus, Rattus norvegicus | F17 | VDSKNFDDYMK | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | F58 | KTHSTFKNTEI | 2 | Homo sapiens, Rattus norvegicus | F58 | KTQSTFKNTEI | 2 | Bos taurus, Mus musculus | K59 | THSTFKNTEIS | 2 | Homo sapiens, Rattus norvegicus | K59 | TQSTFKNTEIS | 1 | Bos taurus | K59 | TQSTFKNTEIN | 1 | Mus musculus | L116 | DGKLILTLTHG | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | L24 | DYMKSLGVGFA | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | M21 | NFDDYMKSLGV | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | N60 | HSTFKNTEISF | 2 | Homo sapiens, Rattus norvegicus | N60 | QSTFKNTEISF | 1 | Bos taurus | N60 | QSTFKNTEINF | 1 | Mus musculus | P39 | ASMTKPTTIIE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P39 | GNMTKPTTIIE | 1 | Bos taurus | R127 | TAVCTRTYEKE | 1 | Homo sapiens | R127 | TAVCTRTYEKQ | 1 | Bos taurus | R127 | SVVSTRTYEKE | 1 | Mus musculus | R127 | NVVSTRTYEKE | 1 | Rattus norvegicus | R79 | TTADDRKVKSI | 2 | Homo sapiens, Bos taurus | R79 | VTADDRKVKSL | 1 | Mus musculus | R79 | VTADDRKVKSV | 1 | Rattus norvegicus | S56 | TLKTHSTFKNT | 1 | Homo sapiens | S56 | IIKTQSTFKNT | 1 | Bos taurus | S56 | TIKTQSTFKNT | 1 | Mus musculus | S56 | TIKTHSTFKNT | 1 | Rattus norvegicus | T37 | QVASMTKPTTI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T37 | QVGNMTKPTTI | 1 | Bos taurus | T54 | ILTLKTHSTFK | 1 | Homo sapiens | T54 | TVIIKTQSTFK | 1 | Bos taurus | T54 | TITIKTQSTFK | 1 | Mus musculus | T54 | TITIKTHSTFK | 1 | Rattus norvegicus | T61 | STFKNTEISFK | 2 | Homo sapiens, Bos taurus | T61 | STFKNTEINFQ | 1 | Mus musculus | T61 | STFKNTEISFQ | 1 | Rattus norvegicus | T74 | VEFDETTADDR | 2 | Homo sapiens, Bos taurus | T74 | IEFDEVTADDR | 1 | Mus musculus | T74 | VEFDEVTADDR | 1 | Rattus norvegicus | T75 | EFDETTADDRK | 2 | Homo sapiens, Bos taurus | T75 | EFDEVTADDRK | 2 | Mus musculus, Rattus norvegicus | Y129 | VSTRTYEKEA | 2 | Mus musculus, Rattus norvegicus | Y129 | VCTRTYEKEA | 1 | Homo sapiens | Y129 | VCTRTYEKQA | 1 | Bos taurus | Y20 | KNFDDYMKSLG | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |